Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-3446
Publication type: Conference poster
Type of review: Not specified
Title: The cost and revenue situation of intravenous administration versus subcutaneous application of Herceptin and MabThera in Switzerland
Authors: Rüthemann, Isabelle
Auerbach, Holger
DOI: 10.21256/zhaw-3446
Conference details: Versorgungsforschung in der Schweiz: das Beispiel Onkologie, Bern, 1. November 2012
Issue Date: 2012
Publisher / Ed. Institution: Schweizerische Akademie der Medizinischen Wissenschaften
Publisher / Ed. Institution: Bern
Language: English
Subject (DDC): 615: Pharmacology and therapeutics
Abstract: In Switzerland, every year about 5’500 women are diagnosed with breast cancer and 1’500 people with non-Hodgkin's lymphoma. The targeted therapy with MabThera® is the standard of care for many patients with Non-Hodgkin’s lymphoma, whereas Herceptin® is approved for the treatment of a certain type of breast cancer. Currently both drugs are administered intravenously (IV), yet a subcutaneous application (SC) is in development. Assuming the same price for the future subcutaneous formulation, this study compared the cost and revenue situation of both application forms. The analysis was performed both in hospital outpatient- and resident oncologists-settings in Switzerland.
URI: https://digitalcollection.zhaw.ch/handle/11475/13926
Fulltext version: Published version
License (according to publishing contract): Licence according to publishing contract
Departement: School of Management and Law
Organisational Unit: Winterthur Institute of Health Economics (WIG)
Appears in collections:Publikationen School of Management and Law

Files in This Item:
File Description SizeFormat 
203409.pdf1.78 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.